Drugs.com New Drug ApplicationsOriginal article
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
NDA FilingTinlarebantPositive
AI Analysis
Summary
Belite Bio completed a rolling submission of a New Drug Application to the FDA for Tinlarebant, a therapeutic candidate for the treatment of Stargardt Disease Type 1. The rolling submission represents progress toward potential regulatory approval of the company's novel degenerative disease therapy.
Outcome Details
Rolling submission completed to U.S. Food and Drug Administration
Importance:7/10
Sentiment:
0.60
NDA FilingRegulatoryStargardt DiseaseOphthalmologyFDA Submission
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on June 12, 2026 9:07 PM